SNDX Syndax Pharmaceuticals, Inc.
$13.69▲ +3.56%
Healthcare
Other
After hours
$13.69▲ +0.00%
Oct 27, 4:00 PM ET
Volume 2.70M
Avg Volume (10D) 3.26M
Key Metrics & Fundamentals
Market Cap
$1.22B
P/E Ratio
–
Div Yield
0.00%
52W Range
12.80 - 25.59
% vs 50 MA
-21.99%
% vs 200 MA
-32.68%
RSI-14
33.3
MACD Histogram
-0.0300
Beta (1Y vs SPY)
0.76
Free Cash Flow
-$30.31M
Gross Rev
$72.79M
Gross Profit
$69.58M
EBITDA
-$36.68M
COGS
$3.21M
Operating Exp
$109.58M
Operating Income
-$40.00M
EBIT
-$40.00M
Pretax Income
-$49.36M
Net Income
-$49.36M
EPS (Diluted)
-0.55
Price & Volume History
Loading chart…
Recent News
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Zacks · Oct 26, 2026 9:00 AM ET
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
GlobeNewswire · Oct 26, 2026 7:00 AM ET
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
GlobeNewswire · Oct 15, 2026 4:01 PM ET
J&J earnings set ‘negative tone’; Shkreli vs. the FTC
BioPharma Dive · Oct 14, 2026 9:31 AM ET
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
Zacks · Oct 14, 2026 8:52 AM ET
Top Midday Decliners
MT Newswires · Oct 13, 2026 2:01 PM ET
Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans.
Barrons.com · Oct 13, 2026 11:24 AM ET
Syndax Pharmaceuticals Selloff After IPF Trial Failure Appears 'Overdone,' BofA Securities Says
MT Newswires · Oct 13, 2026 11:12 AM ET
BofA Securities Adjusts Syndax Pharmaceuticals PT to $23 From $26, Maintains Buy Rating
MT Newswires · Oct 13, 2026 8:09 AM ET
Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed?
Simply Wall St. · Oct 13, 2026 12:34 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See SNDX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.